2008
DOI: 10.1590/s1516-93322008000100004
|View full text |Cite
|
Sign up to set email alerts
|

Análise de custo do tratamento medicamentoso da artrite reumatóide

Abstract: (R$ 1.554.483,43), aquele que utiliza a tripla terapia e depois o biológico (R$ 1.701.286,76), o paciente intolerante ao metotrexato (R$ 2.629.919,14), e por fim o resultado daquele que iniciaria o tratamento já com o infliximabe mais metotrexato (R$ 9.292.879,31 INTRODUÇÃOA reumatologia vem sendo marcada pela introdução de terapias novas e altamente efetivas, mas caras, surgindo à necessidade de correlacionamento entre a sua real necessidade face à probabilidade de bons resultados e custos prováveis. O ques… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
3
0
2

Year Published

2009
2009
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 11 publications
(5 citation statements)
references
References 10 publications
(14 reference statements)
0
3
0
2
Order By: Relevance
“…For the treatment of some pathologies, such as rheumatoid arthritis, some types of drugs such as disease-modifying drugs (DMARDs) are commonly used [82,83,84]. This group of drugs presents a series of chemically unrelated drugs, such as antimalarial drugs, methotrexate, leflunomide, IL-1 receptor antagonists, cytotoxic agents, and biological TNF-α blocking agents [83,85,86].…”
Section: Discussionmentioning
confidence: 99%
“…For the treatment of some pathologies, such as rheumatoid arthritis, some types of drugs such as disease-modifying drugs (DMARDs) are commonly used [82,83,84]. This group of drugs presents a series of chemically unrelated drugs, such as antimalarial drugs, methotrexate, leflunomide, IL-1 receptor antagonists, cytotoxic agents, and biological TNF-α blocking agents [83,85,86].…”
Section: Discussionmentioning
confidence: 99%
“…However, the cost of these agents is high [29,30], which makes it difficult its use in Brazil, especially in small centers, as the studied one. We believe that the economic is one of the most relevant factor for the treatment in Brazil, since the health-related costs have reached unsustainable levels to the two most important paying medical services in the country (Unified Public Health System and Prived health plans) [31]. The public health question if the benefits of innovations drug outweighs its high prices [32].…”
Section: Discussionmentioning
confidence: 99%
“…Portanto, é essencial que o diagnóstico seja realizado o mais cedo possível, a fim de gerenciar e monitorar os recursos de forma adequada (MONTEIRO & ZANINI, 2008).…”
Section: Introductionunclassified